Key takeaways
Zeposia (ozanimod) and Entyvio (vedolizumab) are both medications used to treat ulcerative colitis (UC) in adults. However, they belong to different medication classes and have distinct uses and administration methods. Zeposia is a sphingosine 1-phosphate receptor modulator also approved for relapsing forms of multiple sclerosis (MS), while Entyvio is an integrin antagonist also used for Crohn's disease (CD). Zeposia is taken orally once daily, whereas Entyvio is administered either as an intravenous infusion every two months or as a subcutaneous injection every two weeks. Common side effects of Zeposia include infections and changes in liver tests, while Entyvio may cause headaches, mild infections, and joint pain. You should avoid foods high in tyramine (e.g., aged cheeses, pickled or fermented foods, or alcohol) while taking Zeposia.
